At the molecular level, m⁶A is a widespread internal modification on messenger RNA (mRNA) critical for fine-tuning gene expression post-transcriptionally. Through an elaborate interplay of enzymatic complexes known as “writers,” “erasers,” and “readers,” m⁶A orchestrates fundamental RNA processes such as splicing, stability, transport, translation efficiency, and degradation. The “writers,” mainly methyltransferase-like proteins METTL3 and METTL14, catalyze the methylation of adenosine residues, while “erasers” like FTO and ALKBH5 demethylate these modifications dynamically. “Readers,” including the YTH domain-containing proteins and IGF2BP family, recognize m⁶A marks and guide the fate of modified transcripts, thus establishing a sophisticated regulatory network that can either promote or inhibit oncogenic pathways.

The review dissects how aberrant expression and mutation of these m⁶A regulators disrupt normal RNA metabolism, often tipping the scale towards tumorigenesis. For instance, overexpression of METTL3 is frequently observed to drive malignant transformation by stabilizing oncogene transcripts and enhancing pro-tumorigenic pathways. Conversely, underexpression of erasers like FTO can lead to increased methylation and repression of tumor suppressor genes. This paradoxical impact underscores the nuanced and context-dependent nature of m⁶A modifications across diverse cancer types, contributing to hallmark traits such as unchecked cellular proliferation, evasion of apoptosis, enhanced metastatic potential, and neoangiogenesis.

A particularly striking aspect emphasized in this research is m⁶A’s definitive role in modulating cancer stem cell properties and immune evasion mechanisms. By regulating stability and translation of transcripts encoding stemness factors and immunomodulatory molecules, m⁶A shapes the tumor microenvironment and influences interactions with immune cells. This insight opens new avenues to understand why certain tumors develop resistance to conventional therapies and immune checkpoint blockade, positioning m⁶A as a nexus of immune escape and therapeutic failure.

Moreover, the authors present compelling evidence of m⁶A’s involvement in metabolic reprogramming within tumors. Altered m⁶A patterns affect key enzymes and regulatory RNAs governing metabolic pathways, thereby fine-tuning the adaptation of cancer cells to nutrient-deprived and hypoxic microenvironments. Such metabolic plasticity, driven by epitranscriptomic modifications, equips tumors with enhanced survival capabilities, further complicating treatment outcomes.

From a clinical perspective, the review amplifies the diagnostic and prognostic significance of m⁶A machinery. Aberrant expression profiles of writers, erasers, and readers are increasingly associated with disease progression and patient survival in malignancies such as colorectal carcinoma, hepatocellular carcinoma, and acute myeloid leukemia. Profiling m⁶A regulators thus holds promise as a biomarker framework for early cancer detection and prognosis stratification, potentially revolutionizing personalized oncology.

On the therapeutic front, this research spotlights innovative approaches that target the m⁶A modification landscape. Small-molecule inhibitors, such as STM2457 targeting METTL3 and FB23-2 aimed at FTO, have demonstrated potent antitumor activity by disrupting aberrant methylation signaling. Additionally, RNA-based technologies like CRISPR-dCas13-mediated m⁶A editing introduce a transformative method for locus-specific epitranscriptomic modulation, offering highly precise and reversible intervention strategies.

Combination therapies integrating m⁶A modulation with chemotherapy, radiotherapy, and immunotherapy represent a burgeoning frontier to overcome resistance mechanisms. These synergistic regimens leverage the epigenetic plasticity conferred by m⁶A alterations to sensitize tumors, enhance immune surveillance, and potentiate cytotoxic effects. Clinical trials investigating these combinations could redefine the therapeutic landscape for refractory cancers.

Personalized medicine also stands to benefit immensely from m⁶A research. The dynamic and individualized m⁶A methylation patterns in tumors suggest that patient-specific epitranscriptomic profiling could tailor treatment decisions optimally. Emerging liquid biopsy techniques to monitor circulating m⁶A marks and regulators might enable real-time assessment of therapeutic efficacy and disease progression, thus fine-tuning patient management in a non-invasive manner.

Despite the revolutionary potential, challenges remain regarding the complexity of m⁶A regulatory networks and the risk of systemic side effects given the modification’s ubiquity in normal biology. The pharmacodynamics and delivery systems of m⁶A-targeted therapies require refinement to ensure selectivity and minimize off-target impacts. Continued interdisciplinary research integrating molecular biology, medicinal chemistry, and clinical oncology is critical to translate these insights into safe and effective treatments.

Ultimately, the review by Zhang, Guo, and colleagues decisively establishes m⁶A methylation not merely as a molecular hallmark of cancer but as a central epigenetic orchestrator with vast diagnostic, prognostic, and therapeutic implications. This epitranscriptomic modification emerges as a compelling frontier, heralding a new era of RNA-targeted precision oncology that could reshape how we understand and combat cancer in the coming decades.

Subject of Research:
Article Title: The m⁶A modification in cancer: roles, implications, and its potential in therapy
News Publication Date: 23-Sep-2025
Web References: http://dx.doi.org/10.1186/s43556-025-00314-2
Image Credits: Mei Guo
Keywords: m⁶A, epitranscriptomics, RNA modification, cancer biology, METTL3, FTO, RNA methylation, cancer stem cells, immune evasion, targeted therapy, CRISPR-dCas13, personalized medicine

CSCs share defining characteristics with normal stem cells, including the remarkable ability to self-renew, proliferate indefinitely, and differentiate into diverse tumor cell lineages. The preservation of these stem-like traits is essential for sustained tumor growth, metastasis, and resistance to therapies. Intriguingly, exosomal ncRNAs originating from various sources within the TME, notably the non-CSC tumor cells, have emerged as pivotal regulators that uphold CSC stemness by modulating the genetic and signaling landscape of these crucial cells. This modulation occurs through a targeted influence on genes and pathways intimately linked to stem cell maintenance, underscoring a complex regulatory circuitry that supports CSC vitality.

The role of exosomal ncRNAs in this context is multi-dimensional. Tumor-derived exosomes laden with ncRNAs have been documented to upregulate fundamental stemness markers, including CD44, CD133, OCT4, Sox2, and Nanog across a spectrum of cancers such as pancreatic, oral squamous cell carcinoma, colorectal, osteosarcoma, and nasopharyngeal carcinoma. This upregulation not only perpetuates the stem cell-like state of CSCs but also amplifies their invasive and metastatic potential, along with enhancing resistance to chemotherapeutic agents. Such findings signify that exosomal ncRNAs are critical drivers of aggressive tumor phenotypes and therapeutic recalcitrance via stemness augmentation.

Beyond tumor cells, mesenchymal stem cells (MSCs) residing within the TME exert a profound influence on CSC biology through their secretion of exosomes rich in ncRNAs. MSCs boast intrinsic high plasticity and an adaptive secretome responsive to environmental cues. Bone marrow-derived MSCs (BM-MSCs), for instance, release exosomal microRNAs like miR-155, which inhibit apoptosis and promote proliferation in multiple myeloma cells, concomitantly upregulating key stemness markers and drug resistance proteins. Similarly, BM-MSC-derived miR-142-3p has been shown to activate the Notch signaling pathway by modulating downstream targets such as CD133 and Lgr5, thereby bolstering CSC populations and their stem-like attributes in various cancers.

CAFs, an integral cellular component of the TME, further contribute to CSC stemness modulation via exosomal ncRNA transfer. Under hypoxic conditions, CAFs co-cultured with pancreatic cancer cells elevate the expression of stemness proteins including CD44, CD133, OCT4, and Sox2, leading to a marked increase in CSC populations and enhanced tumor resistance. Additional research has revealed that CAF-derived exosomes carrying circHIF1A act as molecular sponges for miR-580-5p within breast cancer cells, subsequently upregulating CD44 and cultivating stem-like traits that favor tumor progression. These findings shine a spotlight on the essential role of CAFs in remodeling CSC behavior through exosomal ncRNA-mediated communication.

Immune cells embedded in the TME also participate actively in shaping CSC stemness. M2 macrophage-derived exosomes, for example, are replete with miR-27a-3p, which targets thioredoxin-interacting protein (TXNIP) to promote liver CSC maintenance and activation. By manipulating immune signaling pathways, these exosomal ncRNAs facilitate CSC survival and proliferation, illustrating a nuanced mechanism through which immune components within the TME can indirectly sustain tumor aggressiveness.

At the molecular signaling level, exosome-mediated delivery of ncRNAs exerts a decisive influence on several stemness-related pathways crucial for CSC maintenance. The Wnt/β-catenin pathway is a prime example, serving as a linchpin in the self-renewal and undifferentiated state of CSCs. Studies in non-small cell lung cancer have identified long non-coding RNAs such as PKMYT1AR that interact with miR-485-5p to activate this canonical pathway, reinforcing stemness and facilitating tumor initiation. Concurrently, in lung adenocarcinoma, miR-1275 amplifies both Wnt/β-catenin and Notch signaling axes, jointly fostering a stem cell-like phenotype and promoting aggressive disease progression.

Notch signaling itself stands as a critical conduit in the regulation of CSC proliferation, maintenance, and resistance to chemotherapy. Research underscores that exosomal ncRNAs like miR-600 suppress KLF6 expression, resulting in increased Notch1 transcriptional activity which supports stemness and metastatic dissemination in ovarian cancer cells. Such modulation reveals a sophisticated mechanism by which CSCs exploit exosomal ncRNA cargo to fine-tune their self-renewal signaling programs and evade therapeutic pressure.

The PI3K/Akt pathway represents another signaling cascade modulated by exosomal ncRNAs that enhances CSC characteristics. Through intricate regulation of key downstream transcription factors, microRNAs regulate ovarian and endometrial CSC self-renewal and differentiation, maintaining malignant potential. Further complexity is introduced by CAF-secreted miR-146a-5p, which activates STAT3 and mTOR pathways in urothelial bladder cancer, augmenting CSC stemness and resistance to chemotherapeutic agents. Such multifaceted signaling modulation reinforces the central role of exosomal ncRNAs in driving oncogenic pathways that sustain CSCs.

Breast cancer models provide additional insights, where tumor-secreted exosomes enriched with miR-378a-3p and miR-378d target negative regulators such as Numb and DKK3. This targeting leads to activation of the EZH2/STAT3 axis, a pathway intimately tied to CSC maintenance and chemotherapy resistance. These findings demonstrate how ncRNAs can orchestrate a wide array of molecular programs to bolster tumor aggressiveness via continuous support of CSC populations.

Collectively, this body of research underscores the pivotal role of exosomal non-coding RNAs as critical molecular messengers that orchestrate the bidirectional communication between non-CSCs and CSCs. Through the modulation of gene expression and activation of multiple converging signaling pathways, these ncRNAs sustain the stemness phenotype critical for tumor persistence and progression. Therapeutic strategies aimed at targeting these exosomal ncRNAs or their downstream pathways hold tremendous promise for disrupting CSC-driven tumor resilience and improving clinical outcomes.

Advancing this field demands a deeper mechanistic understanding of exosomal ncRNA biogenesis, cargo selection, and cellular uptake dynamics within the TME. Moreover, the heterogeneity of exosomal populations and their context-specific effects highlight the necessity for precision medicine approaches aimed at selectively modulating harmful exosomal signaling without disrupting physiological communication. As research continues to unravel these complex networks, new biomarkers and therapeutic targets for combating cancer stemness and therapy resistance are poised to emerge.

In conclusion, the evolving landscape of cancer research places exosomal non-coding RNAs at the forefront of our understanding of tumor biology. Their ability to mediate intercellular crosstalk between diverse cellular constituents of the tumor microenvironment and regulate the fundamental stemness characteristics of cancer stem cells offers a paradigm-shifting perspective. Harnessing this knowledge could pave the way for innovative diagnostic and treatment modalities that specifically dismantle the molecular foundations of cancer persistence and aggressiveness.

Subject of Research:
Exosomal non-coding RNAs as regulators of cancer stem cell stemness within the tumor microenvironment.

Article Title:
Exosomal non-coding RNAs: mediators of crosstalk between cancer and cancer stem cells.

Article References:
Wang, S., Shu, J., Wang, N. et al. Exosomal non-coding RNAs: mediators of crosstalk between cancer and cancer stem cells. Cell Death Discov. 11, 434 (2025). https://doi.org/10.1038/s41420-025-02726-z

Image Credits:
AI Generated

DOI:
https://doi.org/10.1038/s41420-025-02726-z

Colorectal cancer (CRC) is among the leading causes of cancer-related death worldwide, with metastasis and therapeutic resistance posing significant obstacles to long-term survival. Conventional cancer models, including two-dimensional cultures and xenografts, have proven limited in accurately reflecting tumor heterogeneity and plasticity. Organoid systems have emerged as the most advanced platform, enabling researchers to capture the self-organizing and differentiation potential of cancer cells within a physiologically relevant extracellular matrix. However, existing organoid culture techniques still fall short of mimicking the developmental plasticity observed during tumor progression.

The novel culture condition described by Wu and colleagues ingeniously capitalizes on insights from developmental biology and stem cell research. By manipulating growth factors and extracellular signals, the researchers induced a fetal-like state within colorectal cancer organoids. This state is characterized by enhanced cellular plasticity reminiscent of fetal intestinal epithelium, conferring tumor cells an elevated capacity for lineage switching, migratory potential, and resistance to targeted therapies. This paradigm-shifting approach represents a conceptual leap from mimicking adult tissue architecture to recapitulating embryonic-like phenotypic flexibility.

Critically, the study elucidates the molecular underpinnings governing this reprogrammed state. Transcriptomic analyses reveal that fetal-like organoids display upregulation of developmental pathways including Wnt/β-catenin, Notch, and Hippo signaling axes, which are tightly regulated during embryogenesis but aberrantly co-opted by cancer cells. Furthermore, epigenetic remodeling appears to play a pivotal role, as key histone modifications and chromatin accessibility landscapes in these organoids mirror fetal tissue profiles rather than mature tumors. These findings suggest that therapeutic inhibition of these developmental networks could disrupt tumor plasticity and improve clinical outcomes.

Beyond molecular characterization, the authors validate the functional consequences of their culture system through comprehensive phenotypic assays. Fetal-like organoids demonstrate increased invasiveness in extracellular matrix assays, higher clonogenic potential, and resistance to conventional chemotherapeutic agents such as 5-fluorouracil and oxaliplatin. Of particular note, this plasticity endows cancer cells with the ability to evade therapeutic pressures by transitioning between cellular states, thereby underscoring the clinical relevance of targeting fetal-like reprogramming.

Importantly, this research introduces an adaptable platform for preclinical drug screening tailored to fetal-like tumor states. By integrating patient-derived CRC tissues into the novel culture condition, the authors generate personalized organoids exhibiting this plastic phenotype, enabling drug efficacy testing that accounts for tumor heterogeneity and adaptive resistance. This approach holds promise for accelerating precision oncology strategies that pre-emptively combat tumor evolution and relapse.

The implications of modeling fetal-like plasticity extend beyond colorectal cancer. Similar phenotypic adaptations are reported in other solid tumors, including pancreatic, breast, and lung cancers. As such, the principles established by Wu et al. could catalyze cross-disciplinary research into tumor plasticity mechanisms and foster the development of broad-spectrum therapeutics aimed at hijacking developmental programs usurped by aggressive malignancies.

Technically, the culture system employs a concoction of defined growth factors, including fibroblast growth factor (FGF) family members and transforming growth factor-beta (TGF-β) modulators, finely tuned to recapitulate the fetal intestine niche. This biochemical milieu orchestrates stem cell niche dynamics and epithelial-mesenchymal interactions that are crucial for fetal-like state maintenance. The extracellular matrix composition is also meticulously optimized to balance rigidity and signaling cue presentation, as matrix stiffness influences cell fate decisions and tissue architecture.

From a translational standpoint, the study emphasizes the necessity of dynamic culture environments that simulate the temporal progression of tumor plasticity. Unlike static conventional cultures, this novel condition supports reversible transitions between differentiated and progenitor-like phenotypes, thereby modeling intratumoral heterogeneity more faithfully. This feature is pivotal for dissecting the complex cell state hierarchies underlying metastasis and drug resistance.

Moreover, the authors employ cutting-edge single-cell RNA sequencing and multiplex immunofluorescence imaging to profile the cellular composition of fetal-like organoids at high resolution. These technologies unveil diverse subpopulations within the organoids, including transient amplifying cells, secretory progenitors, and rare stem-like cells. The spatial organization and lineage relationships mapped by these techniques illuminate the cellular circuitry driving plasticity and tumor progression.

The study also confronts the challenge of recapitulating microenvironmental influences by integrating mesenchymal and immune components in co-culture with the organoids. Such multicellular modeling enhances the fidelity of the system by reflecting paracrine signaling and immune surveillance dynamics critical to tumor evolution. This complexity ensures that the fetal-like plasticity observed is not an artifact but a genuine tumor-intrinsic property.

Importantly, Wu and colleagues provide a comprehensive bioinformatic pipeline for analyzing fetal-like state gene signatures, facilitating reproducibility and cross-study comparisons. This resource enables the broader scientific community to identify fetal-like plasticity markers in diverse cancer datasets, promoting biomarker discovery and therapeutic target validation.

As the field progresses, harnessing the power of fetal-like organoids may revolutionize drug discovery pipelines. High-throughput screening using these models could uncover compounds that selectively impair plastic states or reprogram aggressive cancer cells toward terminal differentiation. Such strategies might reduce tumor adaptability and enhance response durability in patients.

In conclusion, the innovative organoid culture condition pioneered by Wu, Kim, and Smith offers an unprecedented window into the fetal-like plasticity of colorectal cancer. By bridging developmental biology with cancer modeling, this work provides a robust platform to interrogate tumor heterogeneity, adaptive resistance, and potential therapeutic vulnerabilities. As the oncology community grapples with evolving drug resistance and disease relapse, harnessing fetal-like plasticity modeling stands as an exciting frontier with profound clinical promise.

Subject of Research: Colorectal cancer plasticity modeled through novel organoid culture conditions

Article Title: Novel organoid culture condition: modeling fetal-like plasticity in colorectal cancer

Article References:
Wu, C., Kim, M.J. & Smith, J.J. Novel organoid culture condition: modeling fetal-like plasticity in colorectal cancer. Cell Res (2025). https://doi.org/10.1038/s41422-025-01170-z

Image Credits: AI Generated

Immune profiling, in its essence, involves the detailed characterization of immune cells and their functional states within the tumor microenvironment. The complexity of the immune landscape in oncology has long posed challenges due to its heterogeneity and dynamic nature. However, technological breakthroughs such as single-cell RNA sequencing, high-dimensional flow cytometry, and multiplex imaging have paved the way for comprehensive immune mapping at an unprecedented resolution. These tools allow clinicians and researchers to dissect the intricate dialogues between tumor cells and immune components, unveiling mechanisms of immune evasion and therapeutic resistance.

The article effectively bridges the gap between laboratory advancements and clinical applicability, painting a future where immune profiling guides treatment decisions with precision. By deploying multi-modal technologies, the authors describe how real-time monitoring of patient immune status could tailor immunotherapeutic regimens, thereby improving response rates and minimizing adverse effects. This paradigm shift from a one-size-fits-all approach to bespoke immuno-oncology treatment promises to drastically improve patient outcomes.

Integral to this development is the ability to detect and quantify specific immune cell subsets, such as cytotoxic T lymphocytes, regulatory T cells, and myeloid-derived suppressor cells, within tumors. Their proportions and activation states serve as biomarkers indicative of how the immune system is interacting with the cancer. Advanced technologies enable simultaneous measurement of multiple parameters per cell, capturing the diversity and plasticity of immune populations that traditional methods might miss. This holistic immune landscape analysis informs prognostic evaluations and helps in identifying candidates most likely to benefit from checkpoint inhibitors or adoptive cell therapies.

Moreover, the study underscores the role of spatial immune profiling, which retains the positional and contextual information of immune cells relative to tumor cells. Techniques like multiplexed immunofluorescence and imaging mass cytometry allow visualization of immune cells in their native tissue architecture. Understanding these spatial relationships is crucial since immune cell infiltration patterns often correlate with clinical prognosis. This spatial perspective adds an essential dimension to immune profiling, advancing beyond mere enumeration towards functional interpretation.

Ravi and colleagues also highlight the integration of machine learning algorithms with immune datasets, facilitating the recognition of complex patterns and predictive signatures within high-dimensional data. Artificial intelligence not only accelerates data processing but also identifies subtle correlations that might be missed by human analysis. These computational approaches enable the development of robust immune classifiers, which could serve as companion diagnostics in clinical trials and routine care.

The translation of immune profiling into clinical practice, however, faces challenges outlined in the article. Standardization of methodologies, reproducibility across laboratories, and costs remain significant hurdles. The authors advocate for collaborative efforts to establish consensus protocols and validation frameworks that ensure data integrity and comparability. Additionally, ethical considerations regarding data privacy and patient consent are discussed as integral to implementing immune profiling technologies responsibly.

Crucially, the paper emphasizes that immune profiling is not restricted to solid tumors but is equally impactful in hematological malignancies. The characterization of bone marrow immune niches and circulating immune cells offers insights into disease progression and treatment responsiveness in leukemias and lymphomas. This breadth of application signifies the universal potential of immune profiling across oncology subfields.

The authors also explore the concept of dynamic immune monitoring, where serial profiling during treatment courses provides feedback on therapeutic efficacy and emerging resistance. This temporal perspective enables oncologists to adapt treatment plans proactively, potentially switching therapies before clinical relapse occurs. The continual assessment of immune milieu thus transforms cancer care into a more responsive and personalized endeavor.

Addressing future directions, the article discusses emerging modalities such as neoantigen profiling and T-cell receptor repertoire sequencing that complement immune cell phenotyping. These approaches deepen the understanding of tumor-specific immune responses and guide the engineering of next-generation immunotherapies with enhanced specificity and durability.

Furthermore, the study touches upon the integration of immune profiling data with other omics layers, including genomics, transcriptomics, and metabolomics, to build comprehensive tumor-immune interactomes. Such multi-omics integration enhances the capacity to unravel complex biological networks underlying tumor immunity and resistance mechanisms. This systems biology perspective is poised to generate novel therapeutic targets and biomarkers.

The clinical trial landscape is also evolving in parallel with immune profiling advancements. The article references ongoing studies incorporating immune monitoring endpoints to stratify patient cohorts and validate predictive biomarkers. This convergence of technology and clinical research is facilitating the iterative refinement of immunotherapy protocols, accelerating translation from bench to bedside.

In its conclusion, the research reaffirms that immune profiling represents a transformative force in oncology, offering unprecedented insights into the immune contexture of cancers. By harnessing the power of advanced technologies and computational analytics, clinicians can deliver immunotherapies with greater precision, efficacy, and safety. The seamless integration of immune profiling into routine oncology practice will require multidisciplinary collaboration, innovative regulatory frameworks, and patient-centered approaches.

This groundbreaking study by Ravi et al. sets a new benchmark for how immune profiling can serve as a critical nexus between rapidly advancing technology and the evolving landscape of cancer treatment. As the field moves forward, these insights will undoubtedly spur continued innovation and improved therapeutic outcomes for cancer patients globally.

Article References:
Ravi, N., Tye, G.J., Dhaliwal, S.S. et al. Immune profiling in oncology: bridging the gap between technology and treatment. Med Oncol 42, 446 (2025). https://doi.org/10.1007/s12032-025-03002-x

Image Credits: AI Generated

In recent years, the dynamic interplay between lipid metabolism and tumor biology has emerged as a pivotal focus in cancer research. Tumor cells are not mere passengers but active architects of their metabolic landscape, rewiring lipid pathways to sustain rapid proliferation and evade immune surveillance. This metabolic reprogramming extends far beyond simple energy storage; it integrates complex signaling networks that shape the tumor microenvironment, dictating cancer progression and therapeutic resistance.

At the cellular level, lipids serve fundamental roles as building blocks of membranes, signaling molecules, and energy reservoirs. Tumor cells exploit these lipids, notably fatty acids, cholesterol, and lipid droplets, to fuel aberrant growth and metastasis. Enzymatic systems such as ATP citrate lyase and acyl-CoA synthetase are upregulated to enable enhanced de novo fatty acid synthesis. Concurrently, fatty acid oxidation (FAO) facilitates invasive behaviors, while the saturation levels of fatty acids modulate membrane fluidity and receptor-mediated signal transduction, reinforcing tumor resilience.

Cholesterol metabolism also undergoes substantial alterations in cancerous tissues. Elevated activity of cholesterol esterification enzymes, particularly acyl-CoA:cholesterol acyltransferase (ACAT), leads to the accumulation of lipid droplets that serve as storage depots within tumor cells. These lipid reservoirs support membrane biosynthesis and act as reservoirs for signaling lipids, directly influencing oncogenic pathways regulated by transcription factors such as SREBP2, and signaling cascades including Hedgehog and Notch. This lipid storage mechanism is increasingly recognized as a key contributor to tumor aggressiveness.

Lipid droplets, far from being passive entities, are dynamically regulated organelles critical for maintaining lipid homeostasis in cancer cells. Proteins like PLIN2 coat these droplets, while transcription factors such as FOXO3 govern their metabolism. Dysregulated lipophagy and lipolysis not only mobilize lipid stores but also generate reactive oxygen species (ROS), which paradoxically can promote tumor survival by activating adaptive stress responses. This paradox underscores the intricate balancing act cancer cells perform to thrive under hostile conditions.

The influence of lipid metabolism extends into the tumor immune microenvironment (TIME), where it fundamentally affects immune cell function and fate. Tumor cells create a metabolically hostile milieu characterized by nutrient competition and oxidative stress, which hampers the efficacy of antitumor immune cells and fosters immunosuppression. This metabolic crosstalk is especially evident in various immune subsets, including T cells, dendritic cells, myeloid-derived suppressor cells (MDSCs), natural killer (NK) cells, and macrophages.

T cells, pivotal effectors of adaptive immunity, undergo metabolic adaptations within the tumor niche. Regulatory T cells (Tregs) preferentially utilize FAO and oxidative phosphorylation (OXPHOS) to meet their energetic needs, facilitating their suppressive roles. In contrast, effector T cells depend largely on glycolytic metabolism, rendering them vulnerable to nutrient deprivation and ROS-induced dysfunction. These metabolic constraints significantly impair effective tumor eradication.

Dendritic cells (DCs), essential for antigen presentation and T cell priming, are also hindered by aberrant lipid accumulation in the tumor microenvironment. Lipid overload disrupts their antigen-processing capacity, suppressing their activation. Interestingly, pharmacological inhibition of FAO in DCs has been shown to restore their immunostimulatory functions, suggesting therapeutic avenues targeting cholesterol and fatty acid metabolism to reverse immune tolerance and potentiate immunotherapy.

MDSCs, notorious for their immunosuppressive capacity, rely on lipid metabolic pathways to sustain their function. Specifically, FAO and arachidonic acid metabolism mediated by fatty acid transporter protein 2 (FATP-2) bolster their ability to inhibit T cell responses. Targeting these pathways suppresses MDSC activity, reawakening antitumor immunity and delaying tumor progression—an insight that opens new doors for combinatorial cancer therapies.

Natural killer (NK) cells require balanced lipid metabolism for optimal cytotoxic function, with the mechanistic target of rapamycin (mTOR) pathway acting as a key regulator. Macrophages within the tumor environment demonstrate polarization into distinct phenotypes. M1 macrophages possess pro-inflammatory and tumoricidal properties, whereas M2-like tumor-associated macrophages (TAMs) utilize FAO and secrete immunosuppressive cytokines such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β) that facilitate tumor growth and immune evasion.

The identification of lipid metabolism-associated molecules as biomarkers is gaining traction in cancer diagnostics. Enzymes like fatty acid synthase (FASN), transporters such as FATP, bioactive lipids including ceramides, oxysterols, and lysophosphatidylcholine (LPC) exhibit correlative expression with tumor progression and immune modulation. Their detection in biological fluids represents a promising strategy for early cancer detection, prognosis, and therapeutic guidance.

From a preventive perspective, alterations in lipid metabolites can herald the incipient stages of oncogenesis. Non-invasive monitoring of these metabolites in blood or tissue harbors immense potential for early screening initiatives. Modulating lipid metabolism, whether by inhibiting fatty acid synthesis pathways or amplifying fatty acid oxidation, offers a prospective avenue for interrupting tumor initiation before malignant transformation manifests clinically.

Immunotherapy, a transformative paradigm in cancer treatment, benefits markedly from integration with lipid-targeted strategies. Inhibitors of lipid uptake molecules like CD36 alleviate immunosuppression by reducing lipid overload in immune cells. Furthermore, lipid-based drug delivery systems, exemplified by liposomes, enhance the precision and efficacy of chemotherapeutic and immunomodulatory agents. Advances in understanding ferroptosis, an iron-dependent form of cell death driven by lipid peroxidation, provide a novel mechanistic target that exploits cancer cells’ metabolic vulnerabilities.

Looking ahead, the clinical translation of these insights hinges on several critical fronts. The refinement of lipid metabolism biomarkers for routine diagnostic use promises to revolutionize early cancer detection paradigms. Concurrently, optimizing lipid-centric drug delivery platforms will enhance therapeutic index and patient outcomes. Integrating immunometabolism within personalized oncology frameworks holds the key to tailoring combinatorial approaches that harness both metabolic modulation and immune activation for superior efficacy.

In summary, lipid metabolism is no longer merely a supporting player but rather a central orchestrator in the complex narrative of tumorigenesis and immune regulation. Its reprogramming empowers cancer cells with survival advantages while sculpting an immunosuppressive microenvironment. Targeting these lipid pathways offers a transformative strategy that bridges early diagnosis, effective prevention, and cutting-edge immunotherapy, heralding a new era in cancer management. Continued rigorous research into these metabolic intricacies will undoubtedly propel the development of next-generation interventions poised to curtail the global cancer burden.

Subject of Research: Lipid metabolism and its role in tumor biology and immune microenvironment with implications for early cancer diagnosis and prevention.

Article Title: Lipid Metabolic Reprogramming and the Tumor Immune Microenvironment: A New Strategy for Early Diagnosis and Cancer Prevention

News Publication Date: 30-Mar-2025

Web References:
https://www.xiahepublishing.com/journal/csp
http://dx.doi.org/10.14218/CSP.2025.00002

Image Credits: Ruihua Shi, Xiaoshuang Liu, Jihua Ren

Keywords: Lipid metabolism, Cancer screening, Immunotherapy, Tumor immune microenvironment, Fatty acid oxidation, Cholesterol metabolism, Lipid droplets, Ferroptosis

CircRNAs are a distinct class of endogenous RNA molecules, characterized by their covalently closed-loop structures produced through a noncanonical splicing mechanism known as back-splicing. Unlike linear RNAs, circRNAs lack free 5′ and 3′ termini, conferring exceptional stability against exonucleases. Initially dismissed as splicing artifacts, advancements in high-throughput sequencing and bioinformatics have redefined circRNAs as critical players in the post-transcriptional regulation of gene expression. These circular molecules act as molecular sponges that sequester microRNAs and RBPs, thereby modulating signaling pathways pivotal to oncogenesis and tumor progression.

Central to the biogenesis and functional regulation of circRNAs are the RNA-binding proteins, a diverse group of proteins that recognize specific RNA motifs and structures. RBPs influence the fate of circRNAs at multiple levels, including their maturation from precursor mRNAs, cellular localization, and interaction dynamics. Proteins such as Quaking (QKI), fused in sarcoma (FUS), specificity protein 1 (SP1), adenosine deaminase acting on RNA 1 (ADAR1), and DExH-box helicase 9 (DHX9) have been identified as key modulators of circRNA formation. These factors employ mechanistic finesse to either promote or suppress circularization, impacting downstream oncogenic pathways.

Specifically, RBPs like QKI enhance circRNA formation by binding intronic sequences flanking circularized exons, thereby facilitating the back-splicing reaction. Similarly, FUS directly interacts with circRNAs, creating feedback loops that sustain the aberrant expression of oncogenic circRNAs, amplifying tumor growth signals. Conversely, ADAR1 mediates adenosine-to-inosine RNA editing events that can disrupt complementary base pairing necessary for circularization, effectively decreasing circRNA abundance. DHX9 operates as an RNA helicase unwinding RNA duplexes, thus impeding the back-splicing machinery and altering circRNA landscapes. This fine balance between promotion and inhibition orchestrated by RBPs profoundly shapes tumor biology.

Recent findings emphasize the role of the tumor microenvironment (TME) in modulating the circRNA-RBP interface. Hypoxic conditions commonly found within solid tumors alter the expression profiles and activities of specific RBPs, thereby affecting circRNA biogenesis. Hypoxia-inducible factors (HIFs) can induce or repress RBPs, indirectly regulating circRNA pools that contribute to adaptive responses such as angiogenesis and metabolic reprogramming. Furthermore, N6-methyladenosine (m6A), the most prevalent internal RNA modification, has been implicated in modifying circRNA structure and function. m6A marks on circRNAs influence their stability, translation potential, and affinity toward RBPs, integrating another regulatory layer within cancer pathogenesis.

The regulatory versatility of circRNAs, modulated by RBPs and epigenetic marks like m6A, elevates the circRNA-RBP nexus as a potential therapeutic target. Contemporary RNA-based technologies, including RNA interference (RNAi), site-directed RNA editing, and the CRISPR/Cas system, are being adapted to manipulate this network. RNAi approaches aim to silence oncogenic RBPs or circRNAs, while CRISPR-Cas13 systems offer programmable RNA targeting capabilities to disrupt deleterious circRNA-RBP interactions precisely. Additionally, strategies utilizing ADAR-mediated RNA editing enable the correction or modulation of RNA transcripts without permanent genomic alterations, promising enhanced safety profiles for clinical applications.

These pioneering techniques allow for tailored modulation of cancer-driving RNA networks with promising specificity and efficacy. By selectively perturbing the circRNA-RBP axis, researchers envision not only halting tumor progression but also overcoming resistance mechanisms limiting current therapies. This approach could reinvigorate immune recognition of tumor cells and reverse malignant phenotypes, carving new paths toward personalized oncology.

Beyond therapeutic potentials, the circRNA-RBP interaction landscape serves as an invaluable biomarker reservoir. The stability of circRNAs in bodily fluids and their tumor-specific expression profiles coupled with RBP signatures offer avenues for non-invasive diagnostics and prognostics. Liquid biopsy platforms detecting circRNA snippets or RBP expression patterns may significantly enhance early cancer detection and monitoring treatment response, heralding a new era of precision medicine.

Overall, the revelation of circRNAs as functional entities, meticulously regulated by RBPs and modulated by the tumor milieu and epitranscriptomic modifications, underscores a profound paradigm shift in understanding RNA biology in cancer. Ongoing research aims to decode the full spectrum of circRNA-RBP interactions and their mechanistic implications across various cancer types, fostering a deeper understanding of tumor heterogeneity and evolution.

As the field advances, integrating multi-omics approaches and single-cell analyses will elucidate how circRNA-RBP networks dynamically respond to genetic and environmental cues in cancer cells. These insights are expected to catalyze the development of next-generation RNA-targeted therapeutics with high precision, reduced toxicity, and improved patient outcomes.

Such comprehensive exploration also demands addressing technical challenges, including efficient delivery systems for RNA therapeutics, avoiding off-target effects, and ensuring long-term safety in clinical settings. Collaborative efforts bridging molecular biology, bioengineering, and clinical oncology are pivotal for translating these promising molecular mechanisms into tangible cancer therapies.

In conclusion, the expanding knowledge surrounding the circRNA-RBP axis not only deepens our comprehension of cancer biology but also catalyzes innovation in molecular therapeutics. Targeting this axis holds the promise of revolutionizing cancer treatment paradigms and opens new horizons for combating one of humanity’s most formidable diseases.

Subject of Research:
Regulation of circRNA generation and function by RNA-binding proteins in cancer biology and therapeutic applications.

Article Title:
Expanded insights into the mechanisms of RNA-binding protein regulation of circRNA generation and function in cancer biology and therapy

News Publication Date:
2025

Web References:
http://dx.doi.org/10.1016/j.gendis.2024.101383

References:
Lixia Li, Chunhui Wei, Yu Xie, Yanyu Su, Caixia Liu, Guiqiang Qiu, Weiliang Liu, Yanmei Liang, Xuanna Zhao, Dan Huang, Dong Wu. Genes & Diseases, Volume 12, Issue 4, 2025, 101383.

Image Credits:
Genes & Diseases

Keywords:
RNA-binding proteins, circular RNAs, cancer biology, tumor proliferation, metastasis, drug resistance, immune evasion, back-splicing, RNA interference, CRISPR-Cas13, RNA editing, epitranscriptomic modification, N6-methyladenosine.